Athira Pharma
18706 North Creek Parkway
Suite 104
Bothell
WA
98011
United States
Tel: 425-620-8501
Website: https://www.athira.com/
Email: Recruiting@athira.com
118 articles with Athira Pharma
-
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
3/28/2023
Athira Pharma, Inc. presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders.
-
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
3/23/2023
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2022, and reviewed recent pipeline and business updates.
-
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
3/8/2023
Athira Pharma, Inc. today announced that members of Athira’s management team will participate in the following upcoming investor conferences: Needham Neurosciences Investor Forum taking place virtually March 15, 2023.
-
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
3/6/2023
Athira Pharma, Inc. today announced that it will participate in two upcoming scientific conferences: American Society for Experimental Neurotherapeutics (ASENT) 2023 Annual Meeting, which will be held virtually from Mar. 13-15, 2023.
-
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
1/31/2023
Athira Pharma, Inc. today announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer.
-
Athira Pharma Provides 2023 Pipeline Outlook
1/5/2023
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, provided an update on its pipeline development programs and outlook for 2023.
-
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
12/21/2022
Athira Pharma, Inc. today announced the publication of preclinical data demonstrating the neuroprotective, neurotrophic and procognitive effects of fosgonimeton (ATH-1017) in preclinical models.
-
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
12/5/2022
Athira Pharma, Inc. today presented data highlighting the potential therapeutic benefits of ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, in a preclinical mouse model of amyotrophic lateral sclerosis (ALS).
-
Athira Pharma’s experimental Alzheimer’s therapy, fosgonimeton, continues to show signs of being able to improve cognition and function in patients.
-
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
12/1/2022
Athira Pharma, Inc. announced it will host a virtual research and development event titled “Enhancing the HGF/MET System to Fight Neurodegenerative Diseases,” on December 7, 2022, from 2:00 p.m. to 3:30 p.m. EST.
-
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
11/29/2022
Athira Pharma, Inc. (NASDAQ: ATHA) today announced the presentation of additional biomarker data from the completed, exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease (AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference.
-
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium
11/28/2022
Athira Pharma, Inc. today announced it will present preclinical data highlighting the therapeutic potential of ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, in amyotrophic lateral sclerosis (ALS), at the Motor Neurone Disease Association’s 33rd International Symposium.
-
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceFosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration
11/21/2022
Athira Pharma, Inc. today announced that additional biomarker data from the completed, exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease was selected as a late-breaking poster presentation at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 29 - December 2, 2022, in San Francisco, California and virtually.
-
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
11/16/2022
Athira Pharma, Inc. today announced data highlighting the potential therapeutic benefits of enhancing the HGF/MET neurotrophic system in preclinical models of Parkinson’s disease (PD) and diabetic neuropathy.
-
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
11/10/2022
Athira Pharma, Inc. announced the company’s financial results for the third quarter ended September 30, 2022 and reviewed recent clinical and corporate updates.
-
Athira Pharma to Present at Stifel 2022 Healthcare Conference
11/9/2022
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced that members of Athira’s management team will participate in the Stifel 2022 Healthcare Conference taking place Nov. 15-16, 2022 in New York City.
-
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
11/7/2022
Athira Pharma, Inc. today announced that it will be presenting preclinical data demonstrating the therapeutic potential of enhancing the HGF/MET neurotrophic system at Neuroscience 2022.
-
An analysis of un-blinded interim data showed fosgonimeton provided clinically meaningful improvements in cognition and function in patients with mild-to-moderate Alzheimer's disease.
-
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
10/17/2022
Athira Pharma, Inc. today announced that following an unblinded interim efficacy and futility analysis, an independent data monitoring committee recommended continuation of the LIFT-AD study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease (AD).
-
Athira Pharma announced Tuesday it will study the stand-alone effects of its Alzheimer’s candidate fosgonimeton (ATH-1017). The drug failed to meet the endpoint in a Phase II study earlier this year.